Stock analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a report issued on Wednesday. The firm set a "sell" rating on the stock.
A number of other research firms have also recently commented on VNRX. Benchmark restated a "hold" rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, March 4th.
Get Our Latest Research Report on VolitionRx
VolitionRx Stock Up 1.6 %
NYSE:VNRX opened at $0.59 on Wednesday. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.09. The stock has a market capitalization of $54.58 million, a PE ratio of -1.64 and a beta of 1.09. The stock's 50-day moving average price is $0.61 and its 200-day moving average price is $0.65.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in VolitionRx in the 4th quarter valued at about $29,000. Millennium Management LLC purchased a new position in VolitionRx in the 4th quarter worth approximately $36,000. Northern Trust Corp lifted its stake in VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Geode Capital Management LLC lifted its stake in VolitionRx by 15.1% in the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company's stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Finally, Lagoda Investment Management L.P. lifted its stake in VolitionRx by 24.3% in the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company's stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.
About VolitionRx
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
